C5a Anaphylatoxin Chemotactic Receptor 1 - Pipeline Review, H2 2020
C5a Anaphylatoxin Chemotactic Receptor 1 - Pipeline Review, H2 2020
SUMMARY
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) pipeline Target constitutes close to 9 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The latest report C5a Anaphylatoxin Chemotactic Receptor 1 - Pipeline Review, H2 2020, outlays comprehensive information on the C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Complement component 5a receptor 1 (C5AR1) or CD88 is a G protein-coupled receptor for C5a. It functions as a complement receptor. Receptor activation stimulates chemotaxis, granule enzyme release, intracellular calcium release and superoxide anion production. The molecules developed by companies in Pre-Registration, Phase II, IND/CTA Filed and Preclinical stages are 1, 1, 1 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Immunology, Dermatology, Gastrointestinal, Infectious Disease, Respiratory, Genito Urinary System And Sex Hormones, Mouth and Dental Disorders, Musculoskeletal Disorders and Oncology which include indications Autoimmune Disorders, Allergic Asthma, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Arthritis, Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome), Bullous Pemphigoid, Chronic Urticaria Or Hives, Churg-Strauss Syndrome, Coronavirus Disease 2019 (COVID-19), Glomerulonephritis, Granulomatosis with Polyangiitis (Wegener's Granulomatosis), Hidradenitis Suppurativa, Huntington Disease, Inflammatory Bowel Disease, Inflammatory Pain, Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease), Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Microscopic Polyangiitis (MPA), Motor Neuron Diseases, Neuroinflammation, Neuropathic Pain (Neuralgia), Pain, Parkinson's Disease, Periodontitis, Pneumonia and Solid Tumor.
Furthermore, this report also reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) pipeline Target constitutes close to 9 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The latest report C5a Anaphylatoxin Chemotactic Receptor 1 - Pipeline Review, H2 2020, outlays comprehensive information on the C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Complement component 5a receptor 1 (C5AR1) or CD88 is a G protein-coupled receptor for C5a. It functions as a complement receptor. Receptor activation stimulates chemotaxis, granule enzyme release, intracellular calcium release and superoxide anion production. The molecules developed by companies in Pre-Registration, Phase II, IND/CTA Filed and Preclinical stages are 1, 1, 1 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Immunology, Dermatology, Gastrointestinal, Infectious Disease, Respiratory, Genito Urinary System And Sex Hormones, Mouth and Dental Disorders, Musculoskeletal Disorders and Oncology which include indications Autoimmune Disorders, Allergic Asthma, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Arthritis, Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome), Bullous Pemphigoid, Chronic Urticaria Or Hives, Churg-Strauss Syndrome, Coronavirus Disease 2019 (COVID-19), Glomerulonephritis, Granulomatosis with Polyangiitis (Wegener's Granulomatosis), Hidradenitis Suppurativa, Huntington Disease, Inflammatory Bowel Disease, Inflammatory Pain, Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease), Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Microscopic Polyangiitis (MPA), Motor Neuron Diseases, Neuroinflammation, Neuropathic Pain (Neuralgia), Pain, Parkinson's Disease, Periodontitis, Pneumonia and Solid Tumor.
Furthermore, this report also reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)
- The report reviews C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics and enlists all their major and minor projects
- The report assesses C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Overview
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Companies Involved in Therapeutics Development
Alsonex Pty Ltd
ChemoCentryx Inc
Dompe Farmaceutici SpA
Innate Pharma SA
MorphoSys AG
Prommune Inc
Teva Pharmaceutical Industries Ltd
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Drug Profiles
ALS-205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avacopan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avdoralimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DF-2593A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Antagonize C5aR for Periodontitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EP-67 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MOR-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMX-205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Antagonize CD88 for Musculoskeletal, Gastrointestinal, Autoimmune and Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Dormant Products
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Discontinued Products
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Product Development Milestones
Featured News &Press Releases
Nov 11, 2020: I-Mab announces preclinical data on differentiated Anti-C5aR Antibody TJ210/MOR210 at SITC 2020
Nov 06, 2020: ChemoCentryx announces plenary session at ACR Convergence 2020 to highlight findings of ADVOCATE phase III trial in ANCA-associated vasculitis
Nov 03, 2020: VFMCRP and ChemoCentryx announce European Medicines Agency has accepted to review the Marketing Authorization Application for avacopan
Oct 28, 2020: ChemoCentryx announces positive topline results of phase II AURORA clinical trial of Avacopan in the treatment of hidradenitis suppurativa (HS)
Oct 27, 2020: I-Mab to present preclinical data of TJ210 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Sep 17, 2020: MorphoSys and I-Mab announce FDA clearance of IND application for MOR210/TJ210 in patients with advanced cancer
Sep 17, 2020: ChemoCentryx announces FDA acceptance of the Avacopan new drug application (NDA) for the treatment of ANCA-associated vasculitis
Jul 29, 2020: Innate Pharma announces publication of EXPLORE COVID-19 translational study findings in Nature
Jul 09, 2020: ChemoCentryx submits New Drug Application to the U.S. FDA for avacopan in ANCA-associated vasculitis
Jun 03, 2020: ChemoCentryx phase III ADVOCATE trial of Avacopan in ANCA-Associated Vasculitis highlighted in oral plenary presentations at EULAR and ERA-EDTA Congresses
Apr 28, 2020: First patient dosed in Avdoralimab phase II clinical trial in covid-19 patients with severe pneumonia
Nov 27, 2019: VFMCRP and ChemoCentryx report positive data for avacopan
Nov 25, 2019: ChemoCentryx and VFMCRP announce positive topline data from pivotal phase III ADVOCATE trial demonstrating avacopan’s superiority over standard of care in ANCA-Associated Vasculitis
Nov 06, 2019: Innate Pharma announces preclinical data presentations on IPH-5401 at SITC 2019
Nov 06, 2019: Innate Pharma announces preclinical data on its Oncology drug candidate IPH-5401 at SITC 2019
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Overview
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Companies Involved in Therapeutics Development
Alsonex Pty Ltd
ChemoCentryx Inc
Dompe Farmaceutici SpA
Innate Pharma SA
MorphoSys AG
Prommune Inc
Teva Pharmaceutical Industries Ltd
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Drug Profiles
ALS-205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avacopan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avdoralimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DF-2593A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Antagonize C5aR for Periodontitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EP-67 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MOR-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMX-205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Antagonize CD88 for Musculoskeletal, Gastrointestinal, Autoimmune and Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Dormant Products
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Discontinued Products
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Product Development Milestones
Featured News &Press Releases
Nov 11, 2020: I-Mab announces preclinical data on differentiated Anti-C5aR Antibody TJ210/MOR210 at SITC 2020
Nov 06, 2020: ChemoCentryx announces plenary session at ACR Convergence 2020 to highlight findings of ADVOCATE phase III trial in ANCA-associated vasculitis
Nov 03, 2020: VFMCRP and ChemoCentryx announce European Medicines Agency has accepted to review the Marketing Authorization Application for avacopan
Oct 28, 2020: ChemoCentryx announces positive topline results of phase II AURORA clinical trial of Avacopan in the treatment of hidradenitis suppurativa (HS)
Oct 27, 2020: I-Mab to present preclinical data of TJ210 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Sep 17, 2020: MorphoSys and I-Mab announce FDA clearance of IND application for MOR210/TJ210 in patients with advanced cancer
Sep 17, 2020: ChemoCentryx announces FDA acceptance of the Avacopan new drug application (NDA) for the treatment of ANCA-associated vasculitis
Jul 29, 2020: Innate Pharma announces publication of EXPLORE COVID-19 translational study findings in Nature
Jul 09, 2020: ChemoCentryx submits New Drug Application to the U.S. FDA for avacopan in ANCA-associated vasculitis
Jun 03, 2020: ChemoCentryx phase III ADVOCATE trial of Avacopan in ANCA-Associated Vasculitis highlighted in oral plenary presentations at EULAR and ERA-EDTA Congresses
Apr 28, 2020: First patient dosed in Avdoralimab phase II clinical trial in covid-19 patients with severe pneumonia
Nov 27, 2019: VFMCRP and ChemoCentryx report positive data for avacopan
Nov 25, 2019: ChemoCentryx and VFMCRP announce positive topline data from pivotal phase III ADVOCATE trial demonstrating avacopan’s superiority over standard of care in ANCA-Associated Vasculitis
Nov 06, 2019: Innate Pharma announces preclinical data presentations on IPH-5401 at SITC 2019
Nov 06, 2019: Innate Pharma announces preclinical data on its Oncology drug candidate IPH-5401 at SITC 2019
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Alsonex Pty Ltd, H2 2020
Pipeline by ChemoCentryx Inc, H2 2020
Pipeline by Dompe Farmaceutici SpA, H2 2020
Pipeline by Innate Pharma SA, H2 2020
Pipeline by MorphoSys AG, H2 2020
Pipeline by Prommune Inc, H2 2020
Pipeline by Teva Pharmaceutical Industries Ltd, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Discontinued Products, H2 2020
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Alsonex Pty Ltd, H2 2020
Pipeline by ChemoCentryx Inc, H2 2020
Pipeline by Dompe Farmaceutici SpA, H2 2020
Pipeline by Innate Pharma SA, H2 2020
Pipeline by MorphoSys AG, H2 2020
Pipeline by Prommune Inc, H2 2020
Pipeline by Teva Pharmaceutical Industries Ltd, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
